Advanced Institute of Finance and Economics, Liaoning University, Liaoning, China.
Graduate School of International Studies, Korea University, Seoul, South Korea.
Neurol India. 2023 Jul-Aug;71(4):710-715. doi: 10.4103/0028-3886.383852.
Several studies have suggested the potential protective role of β2-adrenoreceptor agonist (β2AR-agonist) on the development of Parkinson's disease (PD). However, those could not reflect a different epidemiologic background in eastern countries. We explored β2AR-agonist's effect on PD development by controlling for smoking.
We used the Korean national sample cohort data (from 2002 to 2013) containing 1,025,340 participants (2.2% of the whole population). The subjects over 60 years were included. PD was defined based on the ICD-10 code, which should be diagnosed by neurologists. Atypical Parkinsonisms or ataxic disorders were excluded. We made Set 1 (from 2003 to 2007) and Set 2 (from 2003 to 2008) based on the exposure period for the sensitivity analysis. We observed whether PD had developed during the follow-up periods in each subset.
The PD (Set 1, n = 742; Set 2, n = 699) and non-PD group (Set 1, n = 57,645; Set 2, n = 66,586) were collected. Old age, Medicaid, and asthma were risk factors, whereas smoking was a significant protective factor for PD development. The proportion of β2AR-agonist use was significantly higher in the PD group than in the non-PD group (Set 1, 3.6% vs. 2.4%; Set 2, 4.1% vs. 2.6%). β2AR-agonist use still was a risk factor in developing PD from the multiple logistic regression analysis.
β2-AR-agonist looked like a risk factor rather than a protective factor for PD development. Well-controlled studies reflecting various epidemiologic backgrounds are required to confirm the role of β2AR-agonist.
多项研究表明，β2-肾上腺素能受体激动剂（β2AR-激动剂）对帕金森病（PD）的发展具有潜在的保护作用。然而，这些研究并不能反映东亚国家不同的流行病学背景。我们通过控制吸烟来探讨β2AR-激动剂对 PD 发展的影响。
我们使用了韩国全国样本队列数据（2002 年至 2013 年），其中包含 1,025,340 名参与者（占总人口的 2.2%）。纳入 60 岁以上的患者。PD 的定义基于 ICD-10 编码，应由神经科医生进行诊断。排除不典型帕金森病或共济失调障碍。我们基于暴露期，将数据分为 Set1（2003 年至 2007 年）和 Set2（2003 年至 2008 年），进行敏感性分析。我们观察了在随访期间，每个亚组中 PD 是否已经发生。
我们收集了 PD（Set1，n=742；Set2，n=699）和非 PD 组（Set1，n=57,645；Set2，n=66,586）的数据。老年、医疗补助和哮喘是 PD 的危险因素，而吸烟是 PD 发展的显著保护因素。PD 组中β2AR-激动剂的使用比例明显高于非 PD 组（Set1，3.6% vs. 2.4%；Set2，4.1% vs. 2.6%）。多因素逻辑回归分析表明，β2AR-激动剂的使用仍然是 PD 发病的危险因素。
β2AR-激动剂似乎是 PD 发病的危险因素，而不是保护因素。需要进行具有不同流行病学背景的对照研究，以进一步确认β2AR-激动剂的作用。
